NewSpring Leads Sorcero Series B to Scale AI Life Sciences

Sorcero, the AI-powered intelligence platform for the life sciences sector, has closed a $42.5 million Series B round led by NewSpring Growth. The round also includes participation from Leawood Venture Capital and Blu Ventures, bringing the company’s total capital raised to $59 million. This funding milestone is geared toward accelerating geographic and vertical expansion across medical affairs, safety, scientific communications, and device-focused segments.

Sorcero differentiates itself with an NLP-driven platform that curates and interprets scientific content to support medical affairs and regulatory teams. The fresh capital will fund product expansion, international deployment, and the scaling of a go-to-market model that emphasizes a healthcare-focused, insights-driven engagement approach. The company has positioned itself to help life sciences organizations accelerate the adoption of breakthrough therapies by translating research into usable intelligence for teams across the value chain.

The investor group accompanying NewSpring Growth includes Leawood Venture Capital and Blu Ventures, signaling continued appetite from growth-oriented funds to back AI-enabled incumbents in life sciences. The round’s size and syndicate highlight how growth equity is increasingly becoming a default mechanism for standout AI platforms targeting regulated industries where data quality and domain expertise matter as much as speed.

With the capital, Sorcero plans to expand its footprint beyond core US markets and deepen capabilities in areas like medical affairs and post-market safety, while continuing to scale its platform for a broader set of device and biopharma workflows. As AI adoption in life sciences accelerates, a number of analysts expect the sector to maintain elevated funding levels for the foreseeable future, with emphasis on scalable, compliant, and domain-savvy solutions that drive measurable outcomes.

For strategic observers, Sorcero’s Series B signals a maturation phase in the life sciences AI landscape: strong early-stage entrants prove out their value, attracting dedicated growth funds that can enable rapid scale, customer expansion, and global reach. The combination of Sorcero’s domain focus and its investors’ growth-oriented backing positions the company to play a central role in shaping data-driven medical intelligence across the industry.